Semaphorins are a large family of developmental regulatory signals, characterized by aberrant expression in human cancers. These molecules crucially control cell-cell communication, cell migration, invasion and metastasis, tumor angiogenesis, inflammatory and anti-cancer immune responses. Semaphorins comprise secreted and cell surface-exposed molecules and their receptors are mainly found in the Plexin and Neuropilin families, which are further implicated in a signaling network controlling the tumor microenvironment. Accumulating evidence indicates that semaphorins may be considered as novel clinical biomarkers for cancer, especially for the prediction of patient survival and responsiveness to therapy. Moreover, preclinical experimental studies have demonstrated that targeting semaphorin signaling can interfere with tumor growth and/or metastatic dissemination, suggesting their relevance as novel therapeutic targets in cancer; this has also prompted the development of semaphorin-interfering molecules for application in the clinic. Here we will survey, in diverse human cancers, the current knowledge about the relevance of semaphorin family members, and conceptualize potential lines of future research development in this field.

Mastrantonio, R., You, H., Tamagnone, L., Semaphorins as emerging clinical biomarkers and therapeutic targets in cancer, <<THERANOSTICS>>, 2021; 15 (21): 3262-3277. [doi:10.7150/THNO.54023] [http://hdl.handle.net/10807/169251]

Semaphorins as emerging clinical biomarkers and therapeutic targets in cancer

Mastrantonio, Roberta
Primo
;
Tamagnone, Luca
Ultimo
2021

Abstract

Semaphorins are a large family of developmental regulatory signals, characterized by aberrant expression in human cancers. These molecules crucially control cell-cell communication, cell migration, invasion and metastasis, tumor angiogenesis, inflammatory and anti-cancer immune responses. Semaphorins comprise secreted and cell surface-exposed molecules and their receptors are mainly found in the Plexin and Neuropilin families, which are further implicated in a signaling network controlling the tumor microenvironment. Accumulating evidence indicates that semaphorins may be considered as novel clinical biomarkers for cancer, especially for the prediction of patient survival and responsiveness to therapy. Moreover, preclinical experimental studies have demonstrated that targeting semaphorin signaling can interfere with tumor growth and/or metastatic dissemination, suggesting their relevance as novel therapeutic targets in cancer; this has also prompted the development of semaphorin-interfering molecules for application in the clinic. Here we will survey, in diverse human cancers, the current knowledge about the relevance of semaphorin family members, and conceptualize potential lines of future research development in this field.
2021
Inglese
Mastrantonio, R., You, H., Tamagnone, L., Semaphorins as emerging clinical biomarkers and therapeutic targets in cancer, <<THERANOSTICS>>, 2021; 15 (21): 3262-3277. [doi:10.7150/THNO.54023] [http://hdl.handle.net/10807/169251]
File in questo prodotto:
File Dimensione Formato  
TAMAGNONE 2021.pdf

accesso aperto

Tipologia file ?: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 934.58 kB
Formato Adobe PDF
934.58 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/169251
Citazioni
  • ???jsp.display-item.citation.pmc??? 24
  • Scopus 30
  • ???jsp.display-item.citation.isi??? 30
social impact